Hsinchu, Taiwan

Yu-Sern Lin

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: National Cheng-Kung University. Active years: 2014.

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Yu-Sern Lin: Innovator in Nanoparticle Delivery Systems

Introduction

Yu-Sern Lin is a prominent inventor based in Hsinchu, Taiwan. He has made significant contributions to the field of nanoparticle delivery systems, focusing on enhancing the efficacy of drug delivery mechanisms. With a total of 2 patents, Lin's work is paving the way for advancements in targeted cancer therapies.

Latest Patents

Lin's latest patents include a phosphate-containing nanoparticle delivery vehicle. This innovative delivery system comprises a nanoparticle, an active ingredient, and a phosphodiester moiety that connects the nanoparticle and the active ingredient, forming a prodrug. The nanoparticle delivery vehicle is designed to increase the hydrophilicity of the active ingredient while ensuring specificity against tumor cells. The advantages of this nanoparticle material include biocompatibility, magnetism, and controllable drug release, making it a promising solution for targeted therapies.

Career Highlights

Yu-Sern Lin is affiliated with National Cheng-Kung University, where he continues to advance his research in nanoparticle technology. His work has garnered attention for its potential applications in medical treatments, particularly in oncology.

Collaborations

Lin collaborates with esteemed colleagues, including Jih Ru Hwu and Chen-Sheng Yeh, to further enhance the impact of his research in the field of drug delivery systems.

Conclusion

Yu-Sern Lin's innovative work in nanoparticle delivery systems represents a significant advancement in targeted drug therapies. His contributions are expected to have a lasting impact on the medical field, particularly in the treatment of cancer.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…